RxDoctor Payments Data

Amanda Schnee, MD

Infectious Disease · Greenville, SCNPI 1487093837

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for infectious disease clinicians in SC, where the typical reported total is $781.

$896in general payments, 2019–2025

Across 44 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$162
  • Gilead$145
  • Astellas Pharma US Inc$124
  • AbbVie$98
  • Melinta Therapeutics, LLC$79
  • Paratek Pharmaceuticals, Inc.$74
  • plus $214 from 5 others
$13,000in research payments, 2019–2025

Across 1 payment — averaging $13,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • La Jolla Pharmaceutical Company$13K

What the payments were for

  • Food & beverage$896100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$896 in reported general payments places this provider in the 50th percentile of 102 infectious disease providers in South Carolina.

See all infectious disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$46,808
Medicare patients
233
Services billed
426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala41$152,582
OdefseyEmtricitab/Rilpiviri/Tenof Ala18$63,221
JulucaDolutegravir/Rilpivirine11$38,647
ErtapenemErtapenem Sodium23$13,762
Vancomycin Hcl18$5,426
CeftriaxoneCeftriaxone Sodium13$3,888
Cefadroxil25$829
Cefazolin Sodium11$698
Ciprofloxacin Hcl17$539
Ethambutol Hcl14$358
Doxycycline Hyclate15$337
Amoxicillin15$68

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$145$152,58241 claims
Viiv Healthcare CompanyJuluca$48$38,64711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 102 infectious disease providers in South Carolina.

Other infectious disease in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →